BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Thomsen M, Vitetta L. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics. J Cell Biochem 2019;120:2713-20. [PMID: 30443932 DOI: 10.1002/jcb.27635] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 9.5] [Reference Citation Analysis]
Number Citing Articles
1 Lee SH, You HS, Kang HG, Kang SS, Hyun SH. Association between Altered Blood Parameters and Gut Microbiota after Synbiotic Intake in Healthy, Elderly Korean Women. Nutrients 2020;12:E3112. [PMID: 33053824 DOI: 10.3390/nu12103112] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Li R, Li Y, Li C, Zheng D, Chen P. Gut Microbiota and Endocrine Disorder. In: Chen P, editor. Gut Microbiota and Pathogenesis of Organ Injury. Singapore: Springer; 2020. pp. 143-64. [DOI: 10.1007/978-981-15-2385-4_9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
3 Hertel J, Fässler D, Heinken A, Weiß FU, Rühlemann M, Bang C, Franke A, Budde K, Henning A, Petersmann A, Völker U, Völzke H, Thiele I, Grabe H, Lerch MM, Nauck M, Friedrich N, Frost F. NMR Metabolomics Reveal Urine Markers of Microbiome Diversity and Identify Benzoate Metabolism as a Mediator between High Microbial Alpha Diversity and Metabolic Health. Metabolites 2022;12:308. [DOI: 10.3390/metabo12040308] [Reference Citation Analysis]
4 Ballini A, Scacco S, Boccellino M, Santacroce L, Arrigoni R. Microbiota and Obesity: Where Are We Now? Biology (Basel) 2020;9:E415. [PMID: 33255588 DOI: 10.3390/biology9120415] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
5 Gu C, Zhou Z, Yu Z, He M, He L, Luo Z, Xiao W, Yang Q, Zhao F, Li W, Shen L, Han J, Cao S, Zuo Z, Deng J, Yan Q, Ren Z, Zhao M, Yu S. The Microbiota and It’s Correlation With Metabolites in the Gut of Mice With Nonalcoholic Fatty Liver Disease. Front Cell Infect Microbiol 2022;12:870785. [DOI: 10.3389/fcimb.2022.870785] [Reference Citation Analysis]
6 Ohtani N, Hara E. Gut-liver axis-mediated mechanism of liver cancer: A special focus on the role of gut microbiota. Cancer Sci 2021. [PMID: 34533882 DOI: 10.1111/cas.15142] [Reference Citation Analysis]
7 Singh SP, Anirvan P, Khandelwal R, Satapathy SK. Nonalcoholic Fatty Liver Disease (NAFLD) Name Change: Requiem or Reveille? J Clin Transl Hepatol 2021;9:931-8. [PMID: 34966656 DOI: 10.14218/JCTH.2021.00174] [Reference Citation Analysis]
8 Acharya P, Uppin V, Zarei M, Talahalli RR. Role of n-3 Fatty Acids on Bile Acid Metabolism and Transport in Dyslipidemia: A Review. Lipids 2021;56:125-39. [PMID: 33074554 DOI: 10.1002/lipd.12289] [Reference Citation Analysis]
9 Petrov PD, García-Mediavilla MV, Guzmán C, Porras D, Nistal E, Martínez-Flórez S, Castell JV, González-Gallego J, Sánchez-Campos S, Jover R. A Network Involving Gut Microbiota, Circulating Bile Acids, and Hepatic Metabolism Genes That Protects Against Non-Alcoholic Fatty Liver Disease. Mol Nutr Food Res 2019;63:e1900487. [PMID: 31322321 DOI: 10.1002/mnfr.201900487] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
10 Chen J, Vitetta L. Bile acids and butyrate in the effects of probiotics/synbiotics on nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2019;31:1475-6. [PMID: 31464781 DOI: 10.1097/MEG.0000000000001506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Chen J, Sali A, Vitetta L. The gallbladder and vermiform appendix influence the assemblage of intestinal microorganisms. Future Microbiology 2020;15:541-55. [DOI: 10.2217/fmb-2019-0325] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Sciarrillo CM, Keirns BH, Koemel NA, Anderson KL, Emerson SR. Fibroblast Growth Factor 19: Potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease. Liver Int 2021;41:894-904. [PMID: 33506572 DOI: 10.1111/liv.14802] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Hu S, Chen Y, Zhao S, Sun K, Luo L, Zeng L. Ripened Pu-Erh Tea Improved the Enterohepatic Circulation in a Circadian Rhythm Disorder Mice Model. J Agric Food Chem 2021;69:13533-45. [PMID: 34726418 DOI: 10.1021/acs.jafc.1c05338] [Reference Citation Analysis]
14 Mai BH, Yan LJ. The negative and detrimental effects of high fructose on the liver, with special reference to metabolic disorders. Diabetes Metab Syndr Obes 2019;12:821-6. [PMID: 31213868 DOI: 10.2147/DMSO.S198968] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 6.0] [Reference Citation Analysis]
15 Wang T, Wei X, Chen T, Wang W, Xia X, Miao J, Yin S. Studies of the mechanism of fatty liver formation in Takifugu fasciatus following copper exposure. Ecotoxicol Environ Saf 2019;181:353-61. [PMID: 31207574 DOI: 10.1016/j.ecoenv.2019.06.013] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
16 Chen J, Vitetta L. Gut Microbiota Metabolites in NAFLD Pathogenesis and Therapeutic Implications. Int J Mol Sci 2020;21:E5214. [PMID: 32717871 DOI: 10.3390/ijms21155214] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
17 Zhou Y, Li R, Zheng Y, Song M, Zhang S, Sun Y, Wei M, Fan X. Diosgenin Ameliorates Non-alcoholic Fatty Liver Disease by Modulating the Gut Microbiota and Related Lipid/Amino Acid Metabolism in High Fat Diet-Fed Rats. Front Pharmacol 2022;13:854790. [DOI: 10.3389/fphar.2022.854790] [Reference Citation Analysis]
18 Rajeev R, Seethalakshmi PS, Jena PK, Prathiviraj R, Kiran GS, Selvin J. Gut microbiome responses in the metabolism of human dietary components: Implications in health and homeostasis. Crit Rev Food Sci Nutr 2021;:1-17. [PMID: 34016000 DOI: 10.1080/10408398.2021.1916429] [Reference Citation Analysis]
19 Huang S, Pang D, Li X, You L, Zhao Z, Cheung PC, Zhang M, Liu D. A sulfated polysaccharide from Gracilaria Lemaneiformis regulates cholesterol and bile acid metabolism in high-fat diet mice. Food Funct 2019;10:3224-36. [DOI: 10.1039/c9fo00263d] [Cited by in Crossref: 20] [Cited by in F6Publishing: 5] [Article Influence: 6.7] [Reference Citation Analysis]
20 Kamboj P, Sarkar S, Gupta SK, Bisht N, Kumari D, Alam MJ, Barge S, Kashyap B, Deka B, Bharadwaj S, Rahman S, Dutta PP, Borah JC, Talukdar NC, Banerjee SK, Kumar Y. Methanolic Extract of Lysimachia Candida Lindl. Prevents High-Fat High-Fructose-Induced Fatty Liver in Rats: Understanding the Molecular Mechanism Through Untargeted Metabolomics Study. Front Pharmacol 2021;12:653872. [PMID: 33935766 DOI: 10.3389/fphar.2021.653872] [Reference Citation Analysis]
21 Guo Q, Tang Y, Li Y, Xu Z, Zhang D, Liu J, Wang X, Xia W, Xu S. Perinatal High-Salt Diet Induces Gut Microbiota Dysbiosis, Bile Acid Homeostasis Disbalance, and NAFLD in Weanling Mice Offspring. Nutrients 2021;13:2135. [PMID: 34206629 DOI: 10.3390/nu13072135] [Reference Citation Analysis]
22 Song Q, Zhang X. The Role of Gut–Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC. Biomedicines 2022;10:524. [DOI: 10.3390/biomedicines10030524] [Reference Citation Analysis]
23 Amerikanou C, Kanoni S, Kaliora AC, Barone A, Bjelan M, D'auria G, Gioxari A, Gosalbes MJ, Mouchti S, Stathopoulou MG, Soriano B, Stojanoski S, Banerjee R, Halabalaki M, Mikropoulou EV, Kannt A, Lamont J, Llorens C, Marascio F, Marascio M, Roig FJ, Smyrnioudis I, Varlamis I, Visvikis‐siest S, Vukic M, Milic N, Medic‐stojanoska M, Cesarini L, Campolo J, Gastaldelli A, Deloukas P, Trivella MG, Francino MP, Dedoussis GV; MAST4HEALTH consortium. Effect of Mastiha supplementation on NAFLD: The MAST4HEALTH Randomised, Controlled Trial. Mol Nutr Food Res 2021;65:2001178. [DOI: 10.1002/mnfr.202001178] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
24 Kim JW, Zhou Z, Yun H, Park S, Choi SJ, Lee SH, Lim CW, Lee K, Kim B. Cigarette smoking differentially regulates inflammatory responses in a mouse model of nonalcoholic steatohepatitis depending on exposure time point. Food Chem Toxicol 2020;135:110930. [PMID: 31678261 DOI: 10.1016/j.fct.2019.110930] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
25 Loomba R, Friedman SL, Shulman GI. Mechanisms and disease consequences of nonalcoholic fatty liver disease. Cell 2021;184:2537-64. [PMID: 33989548 DOI: 10.1016/j.cell.2021.04.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
26 Pushpass RG, Alzoufairi S, Jackson KG, Lovegrove JA. Circulating bile acids as a link between the gut microbiota and cardiovascular health: impact of prebiotics, probiotics and polyphenol-rich foods. Nutr Res Rev 2021;:1-20. [PMID: 33926590 DOI: 10.1017/S0954422421000081] [Reference Citation Analysis]
27 Wang Z, Chen WD, Wang YD. Nuclear receptors: a bridge linking the gut microbiome and the host. Mol Med 2021;27:144. [PMID: 34740314 DOI: 10.1186/s10020-021-00407-y] [Reference Citation Analysis]
28 Li H, Xi Y, Xin X, Tian H, Hu Y. Salidroside improves high-fat diet-induced non-alcoholic steatohepatitis by regulating the gut microbiota-bile acid-farnesoid X receptor axis. Biomed Pharmacother 2020;124:109915. [PMID: 31986416 DOI: 10.1016/j.biopha.2020.109915] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
29 Aragonès G, Colom-Pellicer M, Aguilar C, Guiu-Jurado E, Martínez S, Sabench F, Antonio Porras J, Riesco D, Del Castillo D, Richart C, Auguet T. Circulating microbiota-derived metabolites: a "liquid biopsy? Int J Obes (Lond) 2020;44:875-85. [PMID: 31388096 DOI: 10.1038/s41366-019-0430-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 7.0] [Reference Citation Analysis]
30 Zeng Z, Zhou Y, Xu Y, Wang S, Wang B, Zeng Z, Wang Q, Ye X, Jin L, Yue M, Tang L, Zou P, Zhao P, Li W. Bacillus amyloliquefaciens SC06 alleviates the obesity of ob/ob mice and improves their intestinal microbiota and bile acid metabolism. Food Funct 2022;13:5381-95. [PMID: 35470823 DOI: 10.1039/d1fo03170h] [Reference Citation Analysis]
31 Meroni M, Longo M, Dongiovanni P. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. Nutrients. 2019;11. [PMID: 31689910 DOI: 10.3390/nu11112642] [Cited by in Crossref: 19] [Cited by in F6Publishing: 26] [Article Influence: 6.3] [Reference Citation Analysis]
32 Yang ZJ, Zhu MJ, Wang FF, Di ZS, Wang YX, Li LS, Xu JD. Progress in understanding relationship between bile acid metabolic disorder and gut diseases. Shijie Huaren Xiaohua Zazhi 2019; 27(3): 183-189 [DOI: 10.11569/wcjd.v27.i3.183] [Reference Citation Analysis]
33 Zhang S, Wong YT, Tang KY, Kwan HY, Su T. Chinese Medicinal Herbs Targeting the Gut-Liver Axis and Adipose Tissue-Liver Axis for Non-Alcoholic Fatty Liver Disease Treatments: The Ancient Wisdom and Modern Science. Front Endocrinol (Lausanne) 2020;11:572729. [PMID: 33101207 DOI: 10.3389/fendo.2020.572729] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
34 Khan A, Ding Z, Ishaq M, Bacha AS, Khan I, Hanif A, Li W, Guo X. Understanding the Effects of Gut Microbiota Dysbiosis on Nonalcoholic Fatty Liver Disease and the Possible Probiotics Role: Recent Updates. Int J Biol Sci 2021;17:818-33. [PMID: 33767591 DOI: 10.7150/ijbs.56214] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
35 Fitzpatrick E. Understanding susceptibility and targeting treatment in non-alcoholic fatty liver disease in children; moving the fulcrum. Proc Nutr Soc 2019;78:362-71. [DOI: 10.1017/s0029665118002914] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Li P, Hu J, Zhao H, Feng J, Chai B. Multi-Omics Reveals Inhibitory Effect of Baicalein on Non-Alcoholic Fatty Liver Disease in Mice. Front Pharmacol 2022;13:925349. [DOI: 10.3389/fphar.2022.925349] [Reference Citation Analysis]
37 Hu S, Luo L, Zeng L. Tea combats circadian rhythm disorder syndrome via the gut-liver-brain axis: potential mechanisms speculated. Crit Rev Food Sci Nutr 2022;:1-22. [PMID: 35187990 DOI: 10.1080/10408398.2022.2040945] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Wang F, Cui Q, Zeng Y, Chen P. [Gut microbiota-an important contributor to liver diseases]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:595-600. [PMID: 32895142 DOI: 10.12122/j.issn.1673-4254.2020.04.23] [Reference Citation Analysis]
39 Park JW, Kim SE, Lee NY, Kim JH, Jung JH, Jang MK, Park SH, Lee MS, Kim DJ, Kim HS, Suk KT. Role of Microbiota-Derived Metabolites in Alcoholic and Non-Alcoholic Fatty Liver Diseases. Int J Mol Sci 2021;23:426. [PMID: 35008852 DOI: 10.3390/ijms23010426] [Reference Citation Analysis]
40 Chen J, Hall S, Vitetta L. Altered gut microbial metabolites could mediate the effects of risk factors in Covid-19. Rev Med Virol 2021;31:1-13. [PMID: 34546607 DOI: 10.1002/rmv.2211] [Cited by in Crossref: 8] [Article Influence: 8.0] [Reference Citation Analysis]
41 Jiang L, Schnabl B. Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know? Physiology (Bethesda) 2020;35:261-74. [PMID: 32490750 DOI: 10.1152/physiol.00005.2020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
42 Duan L, An X, Zhang Y, Jin, Zhao S, Zhou R, Duan Y, Zhang Y, Liu X, Lian F. Gut microbiota as the critical correlation of polycystic ovary syndrome and type 2 diabetes mellitus. Biomed Pharmacother 2021;142:112094. [PMID: 34449321 DOI: 10.1016/j.biopha.2021.112094] [Reference Citation Analysis]
43 Wang C, Zhu C, Shao L, Ye J, Shen Y, Ren Y. Role of Bile Acids in Dysbiosis and Treatment of Nonalcoholic Fatty Liver Disease. Mediators Inflamm. 2019;2019:7659509. [PMID: 31341422 DOI: 10.1155/2019/7659509] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
44 Chang HJ, Zúñiga A, Conejero I, Voyvodic PL, Gracy J, Fajardo-Ruiz E, Cohen-Gonsaud M, Cambray G, Pageaux GP, Meszaros M, Meunier L, Bonnet J. Programmable receptors enable bacterial biosensors to detect pathological biomarkers in clinical samples. Nat Commun 2021;12:5216. [PMID: 34471137 DOI: 10.1038/s41467-021-25538-y] [Reference Citation Analysis]
45 Mccoubrey LE, Elbadawi M, Basit AW. Current clinical translation of microbiome medicines. Trends in Pharmacological Sciences 2022. [DOI: 10.1016/j.tips.2022.02.001] [Reference Citation Analysis]
46 Mohammadi S, Rostamkhani F, Riyahi Malayeri S, Shirvani H. High-intensity interval training with probiotic supplementation decreases gene expression of NF-κβ and CXCL2 in small intestine of rats with steatosis. Sport Sci Health. [DOI: 10.1007/s11332-021-00829-5] [Reference Citation Analysis]
47 Crommen S, Rheinwalt KP, Plamper A, Simon MC, Rösler D, Fimmers R, Egert S, Metzner C. A Specifically Tailored Multistrain Probiotic and Micronutrient Mixture Affects Nonalcoholic Fatty Liver Disease-Related Markers in Patients with Obesity after Mini Gastric Bypass Surgery. J Nutr 2021:nxab392. [PMID: 34919684 DOI: 10.1093/jn/nxab392] [Reference Citation Analysis]
48 Lee NY, Yoon SJ, Han DH, Gupta H, Youn GS, Shin MJ, Ham YL, Kwak MJ, Kim BY, Yu JS, Lee DY, Park TS, Park SH, Kim BK, Joung HC, Choi IS, Hong JT, Kim DJ, Han SH, Suk KT. Lactobacillus and Pediococcus ameliorate progression of non-alcoholic fatty liver disease through modulation of the gut microbiome. Gut Microbes 2020;11:882-99. [PMID: 31965894 DOI: 10.1080/19490976.2020.1712984] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
49 Sivamaruthi BS, Fern LA, Rashidah Pg Hj Ismail DSN, Chaiyasut C. The influence of probiotics on bile acids in diseases and aging. Biomed Pharmacother 2020;128:110310. [PMID: 32504921 DOI: 10.1016/j.biopha.2020.110310] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
50 Jin LH, Fang ZP, Fan MJ, Huang WD. Bile-ology: from bench to bedside. J Zhejiang Univ Sci B 2019;20:414-27. [PMID: 31090267 DOI: 10.1631/jzus.B1900158] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
51 Zheng Q, Xue C, Gu X, Shan D, Chu Q, Wang J, Zhu H, Chen Z. Multi-Omics Characterizes the Effects and Mechanisms of CD1d in Nonalcoholic Fatty Liver Disease Development. Front Cell Dev Biol 2022;10:830702. [DOI: 10.3389/fcell.2022.830702] [Reference Citation Analysis]
52 Kong Y, Li Y, Dai ZR, Qin M, Fan HL, Hao JG, Zhang CX, Zhong QP, Qi C, Wang P. Glycosaminoglycan from Ostrea rivularis attenuates hyperlipidemia and regulates gut microbiota in high-cholesterol diet-fed zebrafish. Food Sci Nutr 2021;9:5198-210. [PMID: 34532028 DOI: 10.1002/fsn3.2492] [Reference Citation Analysis]